Literature DB >> 33445719

Mortality Risk and Decompensation in Hospitalized Patients with Non-Alcoholic Liver Cirrhosis: Implications for Disease Management.

Ming-Shun Hsieh1,2,3, Kung-Chuan Cheng4, Meng-Lun Hsieh5, Jen-Huai Chiang6, Vivian Chia-Rong Hsieh6.   

Abstract

Here we aimed to assess the mortality risk and distribution of deaths from different complications and etiologies for non-alcoholic liver cirrhosis (NALC) adult inpatients and compare them with that of the general hospitalized adult population. Hospitalized patients with a primary diagnosis of NALC and aged between 30 and 80 years of age from 1999 to 2010 were identified using a population-based administrative claims database in Taiwan. They were matched with a general, non-NALC population of hospitalized patients. Causes of death considered were variceal hemorrhage, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatocellular carcinoma, jaundice, and hepatorenal syndrome. A total of 109,128 NALC inpatients were included and then matched with 109,128 inpatients without NALC. Overall mortality rates were 21.2 (95% CI: 21.0-21.4) and 6.27 (95% CI: 6.17-6.37) per 100 person-years, respectively. Among complications that caused death in NALC patients, variceal hemorrhage was the most common (23.7%, 11.9 per 100 person-years), followed by ascites (20.9%, 10.4 per 100 person-years) and encephalopathy (18.4%, 9.21 per 100 person-years). Among all etiologies, mortality rates were highest for NALC patients with HBV infection (43.7%, 21.8 per 100 person-years), followed by HBV-HCV coinfection (41.8%, 20.9 per 100 person-years), HCV infection (41.2%, 20.6 per 100 person-years), and NAFLD (35.9%, 17.9 per 100 person-years). In this study, we demonstrated that mortality risks in NALC patients may differ with their etiology and their subsequent complications. Patients' care plans, thus, should be formulated accordingly.

Entities:  

Keywords:  ascites; cause of death; chronic hepatitis B; chronic hepatitis C; complications; disease management; hepatic encephalopathy; liver cirrhosis; mortality; nonalcoholic; varices

Mesh:

Year:  2021        PMID: 33445719      PMCID: PMC7828198          DOI: 10.3390/ijerph18020606

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  26 in total

1.  The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

Authors:  T L Fong; A M Di Bisceglie; J G Waggoner; S M Banks; J H Hoofnagle
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

2.  Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.

Authors:  Tung-Hung Su; Tsung-Hui Hu; Chi-Yi Chen; Yi-Hsiang Huang; Wan-Long Chuang; Chun-Che Lin; Chia-Chi Wang; Wei-Wen Su; Ming-Yao Chen; Cheng-Yuan Peng; Rong-Nan Chien; Yi-Wen Huang; Horng-Yuan Wang; Chih-Lin Lin; Sheng-Shun Yang; Tsung-Ming Chen; Lein-Ray Mo; Shih-Jer Hsu; Kuo-Chih Tseng; Tsai-Yuan Hsieh; Fat-Moon Suk; Chi-Tan Hu; Ming-Jong Bair; Cheng-Chao Liang; Yung-Chao Lei; Tai-Chung Tseng; Chi-Ling Chen; Jia-Horng Kao
Journal:  Liver Int       Date:  2016-10-04       Impact factor: 5.828

Review 3.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

4.  Liver cirrhosis and cancer: comparison of mortality.

Authors:  Wankyo Chung; Changik Jo; Woo Jin Chung; Dong Joon Kim
Journal:  Hepatol Int       Date:  2018-03-01       Impact factor: 6.047

5.  Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.

Authors:  Alexander Zipprich; Guadalupe Garcia-Tsao; Sebastian Rogowski; Wolfgang E Fleig; Thomas Seufferlein; Matthias M Dollinger
Journal:  Liver Int       Date:  2012-06-11       Impact factor: 5.828

6.  Incidence, causes, and outcomes of renal failure among cirrhotic patients.

Authors:  Khairy H Morsy; Mohamed A Mekky; Mohamed O Abdel Malek; Wael A Abbas
Journal:  Turk J Gastroenterol       Date:  2015-11       Impact factor: 1.852

7.  Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study.

Authors:  Sonia Ratib; Kate M Fleming; Colin J Crooks; Alex J Walker; Joe West
Journal:  Am J Gastroenterol       Date:  2015-07-14       Impact factor: 10.864

8.  1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998-2009: a large population study.

Authors:  Sonia Ratib; Kate M Fleming; Colin J Crooks; Guruprasad P Aithal; Joe West
Journal:  J Hepatol       Date:  2013-10-12       Impact factor: 25.083

9.  Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.

Authors:  Tsung-Hsing Hung; Chih-Ming Liang; Chien-Ning Hsu; Wei-Chen Tai; Kai-Lung Tsai; Ming-Kun Ku; Jiunn-Wei Wang; Kuo-Lun Tseng; Lan-Ting Yuan; Seng-Howe Nguang; Shih-Cheng Yang; Cheng-Kun Wu; Pin-I Hsu; Deng-Chyang Wu; Seng-Kee Chuah
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

10.  Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.

Authors:  Elliot B Tapper; Neehar D Parikh
Journal:  BMJ       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.